UNSPSC 51283944: Sulfaclomide

This classification denotes a sulfonamide anti-infective agent with the molecular formula C12H13ClN4O2S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier AXA8K5U95M, chemically known as 4-amino-n-(5-chloro-2,6-dimethyl-4-pyrimidinyl)benzenesulfonamide but more generally known as sulfaclomide, which bears U.S. National Institutes of Health Compound Identifier 71168. The European Medicines Agency schedules Sulfaclomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10691MIG.

The term SULFACLOMIDE is an International Non-Proprietary Name. SULFACLOMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC1=C(C(=NC(=N1)C)NS(=O)(=O)C2=CC=C(C=C2)N)CL.

UNSPSC 51283944 Sulfaclomide is a Commodity code for a specific pharmaceutical active ingredient; however, the recent state and local opportunities tagged under this code show little relevant activity aligned with sulfaclomide procurement itself. The two recent records — an Illinois Department of Public Health pharmaceutical warehouse piggyback award (August 2026) and a Seminole County, Florida naloxone and drug deactivation systems procurement (June 2026) — involve different drug products (doxycycline, ciprofloxacin, and naloxone) rather than sulfaclomide. The mismatch suggests either miscoding in the state and local procurement systems or use of the code as a catch-all for pharmaceutical supply chain activities that do not correspond to sulfaclomide specifically. When actual buying patterns diverge from the code name, the recent records do not support treating this code as a reliable signal for sulfaclomide-specific opportunity flow.

The Illinois award — $2,999,999.11 over three years to Chartwell Rx LLC for antibiotic supply via the MMCAP Infuse cooperative purchasing consortium — and the Seminole County IFB for naloxone and drug deactivation systems (1,900 units of naloxone and 800 deactivation systems annually, deliveries to Sanford, Florida) reflect broader state and local pharmaceutical and health-supply procurement, but neither represents sulfaclomide demand. Issuing bodies include state health departments and county health authorities; no standout repeat buyers emerge from the limited sample. Geographic activity touches Illinois and Florida, but the code's actual use does not align with sulfaclomide sourcing, making forecasting of future demand under this code unreliable based on the available record.